News

The New England Journal of Medicine3d
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...
MedPage Today on MSN2d
Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab
Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...
News-Medical.Net on MSN2d
New insights into how myasthenia gravis antibodies disrupt muscle function
People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...
Zacks Investment Research on MSN25d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.
Neurology Advisor3d
Inebilizumab Improves Generalized Myasthenia Gravis Symptoms in Phase 3 Trial
Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...